Compare Stocks: JBIO, ACAD, CDNA, and ELVN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$20.06 -0.3%	$26.91	$19.57 ▼ $30.96	$3.46B	0.88	1.73 million shs	307,532 shs
CDNA CareDx	$66.55 -4.7%	$51.20	$13.95 ▼ $72.51	$3.45B	2.38	920,539 shs	841,251 shs
ELVN Enliven Therapeutics	$43.15 -5.1%	$55.09	$14.78 ▼ $62.32	$3.17B	0.24	1.25 million shs	565,822 shs
JBIO Jade Biosciences	$13.72 -2.5%	$19.34	$8.36 ▼ $28.00	$874.18M	1.64	749,942 shs	159,951 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+0.80%	-2.05%	-28.23%	-23.24%	-7.75%
CDNA CareDx	+4.02%	+8.13%	+37.28%	+146.73%	+359.84%
ELVN Enliven Therapeutics	-3.19%	-1.17%	-23.35%	-10.70%	+131.87%
JBIO Jade Biosciences	-0.35%	-1.95%	-29.30%	-37.33%	+58.80%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$20.06 -0.3%	$26.91	$19.57 ▼ $30.96	$3.46B	0.88	1.73 million shs	307,532 shs
CDNA CareDx	$66.55 -4.7%	$51.20	$13.95 ▼ $72.51	$3.45B	2.38	920,539 shs	841,251 shs
ELVN Enliven Therapeutics	$43.15 -5.1%	$55.09	$14.78 ▼ $62.32	$3.17B	0.24	1.25 million shs	565,822 shs
JBIO Jade Biosciences	$13.72 -2.5%	$19.34	$8.36 ▼ $28.00	$874.18M	1.64	749,942 shs	159,951 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	+0.80%	-2.05%	-28.23%	-23.24%	-7.75%
CDNA CareDx	+4.02%	+8.13%	+37.28%	+146.73%	+359.84%
ELVN Enliven Therapeutics	-3.19%	-1.17%	-23.35%	-10.70%	+131.87%
JBIO Jade Biosciences	-0.35%	-1.95%	-29.30%	-37.33%	+58.80%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.78	Moderate Buy	$32.76	63.34% Upside
CDNA CareDx	2.38	Hold	$54.00	-18.86% Downside
ELVN Enliven Therapeutics	2.82	Moderate Buy	$74.44	72.52% Upside
JBIO Jade Biosciences	2.90	Moderate Buy	$51.75	277.30% Upside

Current Analyst Ratings Breakdown

Latest JBIO, ACAD, CDNA, and ELVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	ELVN Enliven Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$70.00
10/2/2026	CDNA CareDx	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
10/1/2026	JBIO Jade Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$47.00
10/1/2026	ELVN Enliven Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$75.00
10/1/2026	JBIO Jade Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$55.00
9/28/2026	ACAD ACADIA Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$33.00
9/25/2026	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$38.00 ➝ $31.00
9/25/2026	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$41.00 ➝ $35.00
9/25/2026	ACAD ACADIA Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00 ➝ $33.00
9/25/2026	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$37.00 ➝ $33.00
9/25/2026	ACAD ACADIA Pharmaceuticals	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Market Outperform	$36.00 ➝ $33.00

(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$1.14B	3.04	$0.89 per share	22.49	$7.25 per share	2.77
CDNA CareDx	$458.09M	7.52	N/A	N/A	$5.89 per share	11.30
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$7.74 per share	N/A
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	$6.74 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$391M	$2.22	9.04	20.47	N/A	33.42%	9.03%	6.79%	11/4/2026 (Estimated)
CDNA CareDx	-$21.35M	$2.07	32.18	105.64	N/A	24.23%	2.87%	2.17%	11/3/2026 (Estimated)
ELVN Enliven Therapeutics	-$103.69M	-$1.67	N/A	N/A	N/A	N/A	-18.55%	-18.09%	11/11/2026 (Estimated)
JBIO Jade Biosciences	-$127.41M	-$1.92	N/A	N/A	N/A	N/A	-49.11%	-45.62%	N/A

Latest JBIO, ACAD, CDNA, and ELVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/3/2026	Q3 2026	CDNA CareDx	$0.24	N/A	N/A	N/A	$121.95 million	N/A
8/10/2026	Q2 2026	JBIO Jade Biosciences	-$0.66	-$0.76	-$0.10	-$0.76	N/A	N/A
8/5/2026	Q2 2026	ELVN Enliven Therapeutics	-$0.3872	-$0.49	-$0.1028	-$0.49	N/A	N/A
8/4/2026	Q2 2026	ACAD ACADIA Pharmaceuticals	$0.0682	$0.18	+$0.1119	$0.18	$296.55 million	$308.00 million
7/30/2026	Q2 2026	CDNA CareDx	$0.2321	$0.37	+$0.1379	$2.07	$114.05 million	$131.95 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CDNA CareDx	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
JBIO Jade Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	3.39	3.30
CDNA CareDx	N/A	4.58	4.51
ELVN Enliven Therapeutics	N/A	64.07	64.07
JBIO Jade Biosciences	N/A	14.93	14.93

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
CDNA CareDx	N/A
ELVN Enliven Therapeutics	95.08%
JBIO Jade Biosciences	N/A

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	26.20%
CDNA CareDx	2.40%
ELVN Enliven Therapeutics	3.00%
JBIO Jade Biosciences	23.06%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	798	172.31 million	127.16 million	Optionable
CDNA CareDx	765	51.73 million	50.49 million	Optionable
ELVN Enliven Therapeutics	67	73.27 million	71.07 million	Optionable
JBIO Jade Biosciences	55	63.60 million	48.93 million	N/A

JBIO, ACAD, CDNA, and ELVN Headlines

Recent News About These Companies

Jade Biosciences (NASDAQ:JBIO) Stock Rating Reaffirmed as "Buy" by HC Wainwright

October 3 at 1:48 AM | americanbankingnews.com

Analysts Are Bullish on Top Healthcare Stocks: Jade Biosciences (JBIO), Liquidia Technologies (LQDA)

October 2, 2026 | theglobeandmail.com

Analysts Are Bullish on Top Healthcare Stocks: Inogen (INGN), Jade Biosciences (JBIO)

October 2, 2026 | theglobeandmail.com

Jade Biosciences (NASDAQ:JBIO) Stock Keeps Buy Rating at HC Wainwright

October 1, 2026 | marketbeat.com

Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis - Slideshow

September 30, 2026 | seekingalpha.com

Jade Biosciences, Inc. (JBIO) Discusses JADE301 Program Profile and Preclinical Data in Dermatomyositis Transcript

September 30, 2026 | seekingalpha.com

Jade Bioscience Reports Preclinical Data For JADE301

September 30, 2026 | rttnews.com

Transcript : Jade Biosciences, Inc. - Special Call

September 30, 2026 | marketscreener.comM

Jade Biosciences Advances JADE301 Toward Phase 1 Trial In Dermatomyositis

September 30, 2026 | rttnews.com

Jade Biosciences reports JADE301 preclinical data

September 30, 2026 | grafa.comG

Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for ...

September 30, 2026 | finance.yahoo.com

Jade Biosciences Announces Preclinical Data Characterizing JADE301, a Potentially Best-in-Class, Half-Life-Extended Anti-IFN-β Monoclonal Antibody in Development for Dermatomyositis, at EADV 2026

September 30, 2026 | globenewswire.com

Jade Biosciences, Inc. (NASDAQ:JBIO) Receives Average Recommendation of "Moderate Buy" from Analysts

September 25, 2026 | marketbeat.com

Jade Biosciences (NASDAQ:JBIO) Shares Down 9.6% - What's Next?

September 23, 2026 | marketbeat.com

Jade Biosciences (NASDAQ:JBIO) Cut to "Strong Sell" at Wall Street Zen

September 12, 2026 | marketbeat.com

Jade Biosciences (NASDAQ:JBIO) Stock Price Down 4.7% - What's Next?

September 11, 2026 | marketbeat.com

Opaleye Management Inc. Has $3.22 Million Stock Position in Jade Biosciences, Inc. $JBIO

September 11, 2026 | marketbeat.com

Bank of New York Mellon Corp Invests $1.90 Million in Jade Biosciences, Inc. $JBIO

September 9, 2026 | marketbeat.com

Jade Biosciences to Participate in Upcoming Conferences

September 1, 2026 | globenewswire.com

Jade Biosciences: Duration Is The Real Product

August 19, 2026 | seekingalpha.com

Jade Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update

August 10, 2026 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JBIO, ACAD, CDNA, and ELVN Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$20.06 -0.05 (-0.26%)

As of 11:48 AM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

CareDx NASDAQ:CDNA

$66.55 -3.30 (-4.72%)

As of 11:48 AM Eastern

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Enliven Therapeutics NASDAQ:ELVN

$43.15 -2.32 (-5.10%)

As of 11:48 AM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Jade Biosciences NASDAQ:JBIO

$13.72 -0.35 (-2.52%)

As of 11:48 AM Eastern

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. Aerovate Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JBIO, ACAD, CDNA, and ELVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JBIO, ACAD, CDNA, and ELVN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JBIO, ACAD, CDNA, and ELVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

JBIO, ACAD, CDNA, and ELVN Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

CareDx NASDAQ:CDNA

Enliven Therapeutics NASDAQ:ELVN

Jade Biosciences NASDAQ:JBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JBIO, ACAD, CDNA, and ELVN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JBIO, ACAD, CDNA, and ELVN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JBIO, ACAD, CDNA, and ELVN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

JBIO, ACAD, CDNA, and ELVN Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

CareDx NASDAQ:CDNA

Enliven Therapeutics NASDAQ:ELVN

Jade Biosciences NASDAQ:JBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools